Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
Clin Infect Dis
; 40(1): 158-63, 2005 Jan 01.
Article
em En
| MEDLINE
| ID: mdl-15614706
ABSTRACT
BACKGROUND:
This prospective study verified the effect of adherence on the risk of virologic failure.METHODS:
At enrollment in the study, a total of 543 patients who were following a steady (duration, >or=6 months) and effective (viral load, <50 human immunodeficiency virus [HIV] RNA copies/mL) regimen of highly active antiretroviral therapy (HAART) completed a self-reported questionnaire derived from the Adult AIDS Clinical Trials Group Adherence Follow-up Questionnaire. Patients were followed up for the subsequent 6 months to document virologic failure, which was defined as 2 consecutive viral load measurements of >500 HIV RNA copies/mL.RESULTS:
Only the type of treatment and the adherence rate at baseline were significantly associated with the virologic end point. Among patients who reported an adherence rate ofCONCLUSIONS:
Patients receiving NNRTIs report a higher rate of adherence than do patients receiving PIs. Adherence is significantly influenced by the number of pills and daily doses received. Low adherence is a major determinant of virologic failure; however, different therapies have different cutoff values for adherence that determine a significant increment of risk.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Esquema de Medicação
/
HIV-1
/
Cooperação do Paciente
/
Fármacos Anti-HIV
/
Terapia Antirretroviral de Alta Atividade
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article